TrialJournal of the National Cancer Institute2024

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).

Elisa Fontana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.